{"id":"F2021L01332","name":"Therapeutic Goods (Standards for Biologicals—General and Specific Requirements) (TGO 109) Order 2021","slug":"therapeutic-goods-standards-for-biologicals-general-and-specific-requirements-tgo-109-order-2021","collection":"legislative_instrument","jurisdiction":"commonwealth","status":"in_force","isInForce":true,"actNumber":null,"makingDate":null,"administeringDepartment":null,"currentVersion":{"id":441005,"registerId":"F2021L01332-fast-fetch-1775956441338","compilationNumber":null,"startDate":"2026-04-12","status":"InForce","reasons":null,"registeredAt":null},"sections":[{"sectionNumber":"1","sectionType":"section","heading":"Therapeutic Goods (Standards for Biologicals—General and Specific Requirements) (TGO 109) Order 2021","content":"---\nmeta-content-style-type: text/css\nmeta-content-type: application/xhtml+xml; charset=utf-8\nmeta-generator: Aspose.Words for .NET 22.10.0\n---\n\n?xml version=\"1.0\" encoding=\"utf-8\" standalone=\"no\"?>\n\n![Commonwealth Coat of Arms of Australia](image.001.jpeg)\n\n \n\nTherapeutic Goods (Standards for Biologicals—General and Specific Requirements) (TGO 109) Order 2021\n\nI, John Skerritt, as delegate of the Minister for Health and Aged Care, make the following order.\n\nDated 24 September 2021\n\nAdjunct Professor John Skerritt\n\nDeputy Secretary\n\nHealth Products Regulation Group\n\nDepartment of Health\n\n \n\n \n\n \n\nContents\n\nPart 1—Preliminary\n\n1  Name\n\n2  Commencement\n\n3  Authority\n\n4  Definitions\n\n5  Standards\n\n6  Application\n\n7  Transitional arrangements\n\nPart 2—Standard for all biologicals\n\n8  What this Part is about\n\n9  Diseases and conditions that may compromise biologicals\n\n10  Critical materials\n\n11  Microbial contamination control strategy\n\n12  Samples for bioburden testing\n\n13  Bioburden testing requirements\n\n14  Sterilisation\n\n15  Collection from deceased donors\n\n16  Storage and transportation\n\n17  Containers of biologicals\n\nPart 3—Standard for human musculoskeletal tissue products\n\n18  What this Part is about\n\n19  Application of this Part\n\n20  Collection from deceased donors\n\n21  Bioburden testing\n\n22  Demineralised products\n\n23  Freeze‑dried products\n\n24  Storage and transportation\n\nPart 4—Standard for human cardiovascular tissue products\n\n25  What this Part is about\n\n26  Application of this Part\n\n27  Tissue not subjected to a bioburden reduction process\n\n28  Tissue subjected to a bioburden reduction process\n\n29  Heart valves\n\n30  Storage and transportation\n\nPart 5—Standard for human ocular tissue products\n\n31  What this Part is about\n\n32  Application of this Part\n\n33  Collection\n\n34  Storage and transportation\n\n35  Excised cornea—testing of storage medium etc.\n\n36  Containers\n\n37  Examination and evaluation\n\nPart 6—Standard for human skin products\n\n38  What this Part is about\n\n39  Application of this Part\n\n40  Processing etc.\n\n41  Bioburden testing\n\n42  Freeze‑dried products\n\n43  Storage and transportation\n\nPart 7—Standard for human amnion products\n\n44  What this Part is about\n\n45  Application of this Part\n\n46  Collection etc.\n\n47  Terminal sterilisation\n\n48  Dehydrated or freeze‑dried products\n\n49  Storage and transportation\n\n \n\nPart 1—Preliminary\n\n1  Name\n\n (1) This instrument is the Therapeutic Goods (Standards for Biologicals—General and Specific Requirements) (TGO 109) Order 2021.\n\n (2) This instrument may also be cited as TGO 109.\n\n2  Commencement\n\n (1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.\n\n \n\n- Commencement information\n- Column 1 Column 2 Column 3\n- Provisions Commencement Date/Details\n- 1. The whole of this instrument 30 September 2021. 30 September 2021\n\n\nNote: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.\n\n (2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.\n\n3  Authority\n\n  This instrument is made under section 10 of the Therapeutic Goods Act 1989.\n\n4  Definitions\n\nNote: A number of expressions used in this instrument are defined in subsection 3(1) of the Act, including the following:\n\n(a) bioburden;\n\n(b) biological;\n\n(c) container;\n\n(d) manufacture;\n\n(e) manufacturing site;\n\n(f) standard;\n\n(g) supply.\n\n  In this instrument:\n\nAct means the Therapeutic Goods Act 1989.\n\nallogeneic use, in relation to a biological that comprises, contains or is derived from HCT materials, means administration to, or application in the treatment of, a person other than the person from whom the HCT materials used in the manufacture of the biological were collected.\n\nasystole, in relation to a donor of HCT materials, means the reference time for cardiac death, being:\n\n (a) the documented pronounced time of death; or\n\n (b) if death is not witnessed—the last time the donor was known to be alive; or\n\n (c) if the donor of the HCT materials is also a solid organ donor—the cross clamp time.\n\nautologous use, in relation to a biological that comprises, contains or is derived from HCT materials, means administration to, or application in the treatment of, the person from whom the HCT materials used in the manufacture of the biological were collected.\n\ncritical materials means all the materials, other than HCT materials, used in the manufacture of a biological that may directly affect the quality, safety or efficacy of the biological.\n\ncryopreservation, in relation to a biological, means suspension in a medium containing a suitable cryoprotectant and cooling according to a method that has been validated to allow maintenance for long periods.\n\nNote: Other grammatical forms of the word cryopreservation (such as cryopreserved) have a corresponding meaning (see section 18A of the Acts Interpretation Act 1901).\n\nEBAANZ Standards for Eye Donation and Eye Tissue Banking means the document titled EBAANZ Medical and Quality Standards for Eye Donation and Eye Tissue Banking (Edition 2, April 2009) published by the Eye Bank Association of Australia and New Zealand (EBAANZ), as in force or existing at the commencement of this instrument.\n\nNote: The document is published on the Eye Bank Association of Australia and New Zealand (EBAANZ) website at http://www.ebaanz.org/.\n\nfaecal microbiota transplant product has the same meaning as in the Regulations.\n\nGuidance on Virus Validation Studies means the document titled Note for guidance on virus validation studies: the design, contribution and interpretation of studies validating the inactivation and removal of viruses (February 1996) published by the European Medicines Agency, as in force or existing at the commencement of this instrument.\n\nNote: The document is published on the European Medicines Agency website at www.ema.europa.eu/en.\n\nHCT materials means one or more of the following materials:\n\n (a) human cells;\n\n (b) human tissues;\n\nthat are collected for use in the manufacture of a biological and are:\n\n (c) materials intended to comprise, or be contained in, the biological; or\n\n (d) materials from which the biological is intended to be derived.\n\nNote: Human cells and human tissues include human musculoskeletal tissue, human cardiovascular tissue, human ocular tissue, human skin, and human amnion.\n\nhuman amnion product means a biological that comprises, contains or is derived from human amnion.\n\nhuman cardiovascular tissue product means a biological that comprises, contains or is derived from human cardiovascular tissue, including aortic, pulmonary, mitral or tricuspid heart valves or any part of such valves, conduit or greater vessel graft, peripheral vascular tissue graft, or pericardial graft.\n\nhuman ocular tissue product means a biological that comprises, contains or is derived from human ocular tissue, including the eye globe, cornea or sclera.\n\nhuman musculoskeletal tissue product means a biological that comprises, contains or is derived from human musculoskeletal tissue, including bone, cartilage, fascia lata, ligament, muscle, and tendon.\n\nhuman skin product means a biological that comprises, contains or is derived from human skin.\n\nmicroorganism or microbe includes a bacterium, fungus, mycoplasma and rickettsia, but does not include a virus or prion.\n\nNote: Other grammatical forms of the words microorganism and microbe have a corresponding meaning (see section 18A of the Acts Interpretation Act 1901).\n\nExample: Microbe and microbial have corresponding meanings.\n\nminimal manipulation has the same meaning as in the Regulations.\n\nprocessing, in relation to HCT materials, means any activity involved in the preparation, manipulation, preservation for storage and packaging of the materials.\n\nRegulations means the Therapeutic Goods Regulations 1990.\n\nskin means the outer integument or covering of the body, consisting of the dermis and the epidermis and resting on subcutaneous tissue.\n\nspecified microorganism means a microorganism of clinical significance that, if detected, necessitates rejection of HCT materials or a biological.\n\nTGA Approach to TSE means the document titled Transmissible Spongiform Encephalopathies (TSE): TGA approach to minimising the risk of exposure (Version 2.0, April 2014) published by the Therapeutic Goods Administration, as in force or existing from time to time.\n\nNote: The TGA Approach to TSE is published on the Therapeutic Goods Administration website at www.tga.gov.au.\n\ntransportation means the transfer of a substance, material or product, within or between premises including manufacturing sites, under appropriate controlled conditions.\n\n5  Standards\n\n (1) The matters specified in Part 2 constitute a standard for all biologicals.\n\n (2) The matters specified in Part 3 constitute a standard for human musculoskeletal tissue products that are subjected to only minimal manipulation.\n\n (3) The matters specified in Part 4 constitute a standard for human cardiovascular tissue products that are subjected to only minimal manipulation and are manufactured for allogeneic use only.\n\n (4) The matters specified in Part 5 constitute a standard for human ocular tissue products that are subjected to only minimal manipulation and are manufactured for allogeneic use only.\n\n (5) The matters specified in Part 6 constitute a standard for human skin products that are subjected to only minimal manipulation.\n\n (6) The matters specified in Part 7 constitute a standard for human amnion products that are subjected to only minimal manipulation.\n\nNote 1: Part 2 constitutes a general standard that applies to all biologicals, whether or not the biological is also subject to a standard specified in Part 3, 4, 5, 6 or 7.\n\nNote 2: Parts 3 to 7 constitute specific standards that apply to certain human musculoskeletal tissue products, human cardiovascular tissue products, human ocular tissue products, human skin products, and human amnion products, respectively.\n\nExample: Human musculoskeletal tissue products to which Part 3 applies must comply with both Parts 2 and 3.\n\n6  Application\n\n (1) Subject to subsection (2), this instrument applies to biologicals.\n\n (2) This instrument does not apply to biologicals that are:\n\n (a) faecal microbiota transplant products; or\n\n (b) mentioned in item 13 of Schedule 5A to the Regulations, subject to compliance with the condition specified in that item; or\n\n (c) samples of HCT materials that are:\n\n (i) biopsied for in vitro diagnostic examination; and\n\n (ii) not for further manufacture, or reintroduction or transplant to a person.\n\n7  Transitional arrangements\n\n (1) In this section:\n\n  former instruments means the:\n\n (a) Therapeutic Goods Order No. 83 Standards for human musculoskeletal tissue, as in force immediately before the commencement of the repeal instrument; and\n\n (b) Therapeutic Goods Order No. 84 Standards for human cardiovascular tissue, as in force immediately before the commencement of the repeal instrument; and\n\n (c) Therapeutic Goods Order No. 85 Standards for human ocular tissue, as in force immediately before the commencement of the repeal instrument; and\n\n (d) Therapeutic Goods Order No. 86 Standards for human skin, as in force immediately before the commencement of the repeal instrument.\n\n  former provisions means the following provisions of the Therapeutic Goods Order No. 88 Standards for donor selection, testing, and minimising infectious disease transmission via therapeutic goods that are human blood and blood components, human tissues and human cellular therapy products, as in force immediately before the commencement of the repeal instrument:\n\n (a) subsection 9(13); and\n\n (b) subsection 9(14); and\n\n (c) subsection 9(15); and\n\n (d) section 12; and\n\n (e) section 13.\n\n  repeal instrument means the Therapeutic Goods (Standards for Biologicals) Repeal Instrument 2021.\n\n  transition period means the period beginning on 30 September 2021 and ending on 30 September 2022.\n\n (2) Despite the repeal of the former instruments and former provisions by the repeal instrument, the former instruments and former provisions continue to apply for the duration of the transition period, such that the standards for biologicals constituted by the former instruments and former provisions may be conformed with as an alternative to the standards for biologicals constituted by this instrument.\n\n\n\n\nPart 2—Standard for all biologicals\n\n8  What this Part is about\n\nThis Part specifies general requirements that must be met in the manufacture of all biologicals, including requirements relating to the HCT materials used in the manufacture of those biologicals.\n\nUnless otherwise specified, the requirements in this Part apply to all biologicals, including a biological that is subject to a specific standard in Parts 3 to 7 of this instrument.\n\n9  Diseases and conditions that may compromise biologicals\n\n  A biological must not be manufactured using HCT materials collected from a donor who is known to have a disease or condition that may compromise the quality, safety or efficacy of the biological, unless:\n\n (a) criteria for donor selection and periods of donor ineligibility, based on validated data or documented evidence from relevant scientific literature, are applied that support and justify the quality, safety and efficacy of the biological, and the application of the criteria is documented; or\n\n (b) in any case where it is not possible to comply with paragraph (a)—a registered medical practitioner acting for or on behalf of the manufacturer or the sponsor has agreed to, and documented the rationale for, the use of the HCT materials in the manufacture of the biological.\n\n10  Critical materials\n\n (1) The critical materials used in the manufacture of a biological must:\n\n (a) not be contaminated with, or be likely to introduce, microorganisms or other infectious disease agents; and\n\n (b) not adversely affect the quality, safety or efficacy of the biological; and\n\n (c) where the critical materials are solutions that come into contact with HCT materials or biologicals (other than critical materials mentioned in paragraph (d))—be manufactured under an approved quality management system and either:\n\n (i) be supplied as a sterile solution; or\n\n (ii) satisfy sterility requirements specified in an applicable standard; and\n\n (d) where the critical materials are non-sterile antimicrobial agents used in a bioburden reduction process for HCT materials—be passed through a 0.22µm filter prior to use in the bioburden reduction process; and\n\n (e) where the critical materials are of human or animal origin (other than HCT materials)—meet the requirements set out in:\n\n (i) the TGA Approach to TSE; and\n\n (ii) the Guidance on Virus Validation Studies.\n\nCritical materials not included in the Register\n\n (2) The following information in relation to critical materials that are not included in the Register must be available and documented:\n\n (a) screening tests performed and quality control specifications, including criteria and limits for tests; and\n\n (b) storage conditions.\n\n11  Microbial contamination control strategy\n\n  A risk-based microbial contamination control strategy, which considers the nature of HCT materials and biologicals, must:\n\n (a) be implemented to minimise intrinsic and extrinsic microbial contamination of HCT materials and biologicals; and\n\n (b) specify storage, handling and transportation requirements (including in relation to temperature and duration) for the HCT materials and biologicals.\n\n12  Samples for bioburden testing\n\n (1) Samples must be taken for bioburden testing.\n\n (2) Samples must be:\n\n (a) taken using a validated sampling technique; and\n\n (b) tested using a validated test method.\n\nNote: Subsections (1) and (2) apply in relation to all biologicals, other than human ocular tissue products to which Part 5 applies.\n\n (3) This section does not apply in relation to human ocular tissue products to which Part 5 applies.\n\nNote: Part 5 specifies bioburden testing requirements in relation to human ocular tissue products that are subjected to only minimal manipulation and are manufactured for allogeneic use only. However, subsections (1) and (2) apply in relation to all other human ocular tissue products.\n\n13  Bioburden testing requirements\n\n (1) Written specifications for HCT materials and biologicals must include specified microorganisms determined on the basis of a risk assessment.\n\n (2) Samples must demonstrate that HCT materials are free from contamination with specified microorganisms.\n\n (3) Samples must demonstrate that biologicals are:\n\n (a) free from microbial contamination; or\n\n (b) if, on the basis of a risk assessment, it is not necessary for the biological to be free from microbial contamination—free from contamination with specified microorganisms.\n\n (4) This section does not apply in relation to:\n\n (a) human cardiovascular tissue products to which Part 4 applies; and\n\n (b) human ocular tissue products to which Part 5 applies.\n\nNote 1: Part 4 provides that human cardiovascular tissue products that are subjected to only minimal manipulation and are manufactured for allogeneic use only, and human cardiovascular tissue used in the manufacture of those products, must be free from microbial contamination. However, this section applies in relation to all other human cardiovascular tissue products.\n\nNote 2: Part 5 specifies bioburden testing requirements in relation to human ocular tissue products that are subjected to only minimal manipulation and are manufactured for allogeneic use only. However, this section applies in relation to all other human ocular tissue products.\n\n (5) Subsection (3) does not apply in relation to:\n\n (a) human musculoskeletal tissue products to which Part 3 applies; and\n\n (b) human skin products to which Part 6 applies.\n\nNote 1: Part 3 provides that human musculoskeletal tissue products that are subjected to only minimal manipulation must be free from microbial contamination, and human musculoskeletal tissue used in the manufacture of those products must be free from contamination with specified microorganisms. However, subsection (3) applies in relation to all other human musculoskeletal tissue products.\n\nNote 2: Part 6 provides that human skin products that are subjected to only minimal manipulation and human skin used in the manufacture of those products must be free from contamination with specified microorganisms. However, subsection (3) applies in relation to all other human skin products.\n\n14  Sterilisation\n\n  The sterilisation process for a biological that is terminally sterilised must be validated to ensure a maximal sterility assurance level of 10-6.\n\n15  Collection from deceased donors\n\n (1) HCT materials must be collected from a deceased donor as soon as possible after asystole, and collection must be completed:\n\n (a) if the body has been refrigerated below 10°C within 12 hours of asystole—not later than 24 hours after asystole; or\n\n (b) if paragraph (a) does not apply—not later than 15 hours after asystole.\n\n (2) This section does not apply in relation to:\n\n (a) human musculoskeletal tissue products to which Part 3 applies; and\n\n (b) human ocular tissue products to which Part 5 applies; and\n\n (c) human amnion products to which Part 7 applies.\n\nNote 1: Part 3 provides requirements in relation to the collection of human musculoskeletal tissue used in the manufacture of human musculoskeletal tissue products that are subjected to only minimal manipulation. However, this section applies in relation to all other human musculoskeletal tissue products.\n\nNote 2: Part 5 provides requirements in relation to the collection of human ocular tissue used in the manufacture of human ocular tissue products that are subjected to only minimal manipulation and are manufactured for allogeneic use only. However, this section applies in relation to all other human ocular tissue products.\n\nNote 3: Part 7 provides requirements in relation to the collection of human amnion used in the manufacture of human amnion products that are subjected to only minimal manipulation. However, this section applies in relation to all other human amnion products.\n\n16  Storage and transportation\n\nHCT materials\n\n (1) Immediately following collection and prior to processing, HCT materials must be:\n\n (a) stored as follows:\n\n (i) at less than 10°C for not longer than 72 hours; or\n\n (ii) as otherwise validated by the manufacturer to prevent microbial proliferation and to ensure the quality, safety and efficacy of the biological manufactured using the HCT materials; and\n\n (b) transported in a manner that ensures the relevant storage conditions specified in paragraph (a) are maintained during transportation.\n\n (2) Subsection (1) does not apply in relation to:\n\n (a) human cardiovascular tissue products to which Part 4 applies; and\n\n (b) human skin products to which Part 6 applies; and\n\n (c) human amnion products to which Part 7 applies.\n\nNote 1: Part 4 provides storage and transportation requirements in relation to cardiovascular tissue used in the manufacture of cardiovascular tissue products that are subjected to only minimal manipulation and are manufactured for allogeneic use only. However, subsection (1) applies in relation to all other human cardiovascular tissue products.\n\nNote 2: Part 6 provides storage and transportation requirements in relation to human skin used in the manufacture of human skin products that are subjected to only minimal manipulation. However, subsection (1) applies in relation to all other human skin products.\n\nNote 3: Part 7 provides storage and transportation requirements in relation to human amnion used in the manufacture of human amnion products that are subjected to only minimal manipulation. However, subsection (1) applies in relation to all other human amnion products.\n\n (3) HCT materials that are collected and transported for use in the manufacture of a biological must be packaged using aseptic technique and with at least one moisture impermeable barrier.\n\nBiologicals\n\n (4) Biologicals must be stored and transported under conditions that are validated, including justified time and temperature specifications, to ensure the quality and safety of the biologicals.\n\n (5) Subsection (4) does not apply in relation to:\n\n (a) human musculoskeletal tissue products to which Part 3 applies; and\n\n (b) human cardiovascular tissue products to which Part 4 applies; and\n\n (c) human ocular tissue products to which Part 5 applies; and\n\n (d) human skin products to which Part 6 applies; and\n\n (e) human amnion products to which Part 7 applies.\n\nNote 1: Part 3 provides storage and transportation requirements in relation to human musculoskeletal tissue products that are subjected to only minimal manipulation. However, subsection (4) applies in relation to all other human musculoskeletal tissue products.\n\nNote 2: Part 4 provides storage and transportation requirements in relation to human cardiovascular tissue products that are subjected to only minimal manipulation and are manufactured for allogeneic use only. However, subsection (4) applies in relation to all other human cardiovascular tissue products.\n\nNote 3: Part 5 provides storage and transportation requirements in relation to human ocular tissue products that are subjected to only minimal manipulation and are manufactured for allogeneic use only. However, subsection (4) applies in relation to all other human ocular tissue products.\n\nNote 4: Part 6 provides storage and transportation requirements in relation to human skin products that are subjected to only minimal manipulation. However, subsection (4) applies in relation to all other human skin products.\n\nNote 5: Part 7 provides storage and transportation requirements in relation to human amnion products that are subjected to only minimal manipulation. However, subsection (4) applies in relation to all other human amnion products.\n\n (6) A biological that is returned to its manufacturer cannot be released for supply unless:\n\n (a) the biological was at all times stored and transported in accordance with applicable storage and transportation requirements in relation to the biological; and\n\n (b) the labelling and packaging of the biological has not been compromised.\n\n17  Containers of biologicals\n\n (1) A biological must be sealed within a sterile container and must be at least double packaged so as to:\n\n (a) prevent ingress or egress of all materials; and\n\n (b) ensure that any breach of integrity of the container and packaging is evident.\n\n (2) This section does not apply in relation to human ocular tissue products to which Part 5 applies.\n\nNote: Part 5 provides requirements in relation to containers of human ocular tissue products that are subjected to only minimal manipulation and are manufactured for allogeneic use only. However, this section applies in relation to all other human ocular tissue products.\n\n\n\n\nPart 3—Standard for human musculoskeletal tissue products\n\n18  What this Part is about\n\nThis Part specifies requirements that must be met in the manufacture of human musculoskeletal tissue products that have been subjected to only minimal manipulation, including requirements relating to human musculoskeletal tissue that is collected for use in the manufacture of those products.\n\nUnless otherwise specified, a biological to which this Part applies must meet the general requirements in Part 2 in addition to the specific requirements in this Part.\n\n19  Application of this Part\n\n  This Part applies in relation to human musculoskeletal tissue products that have been subjected to only minimal manipulation.\n\n20  Collection from deceased donors\n\n (1) The collection of human musculoskeletal tissue from a deceased donor must commence as soon as possible after asystole and:\n\n (a) if the body has been refrigerated below 10°C within 12 hours after asystole—not later than 24 hours after asystole; or\n\n (b) if paragraph (a) does not apply—not later than 15 hours after asystole.\n\n (2) The collection of human musculoskeletal tissue from a deceased donor must be completed within 36 hours after asystole.\n\n21  Bioburden testing\n\nTissue not subjected to processing\n\n (1) Human musculoskeletal tissue that is not subjected to processing prior to packaging must be sampled at the time of collection for bioburden testing.\n\n (2) Human musculoskeletal tissue sampled in accordance with subsection (1) must be tested for bioburden and:\n\n (a) demonstrate no microbial contamination; or\n\n (b) be rejected for therapeutic use if microbial contamination is demonstrated; or\n\n (c) be subjected to further processing in accordance with subsection (3) if microbial contamination is demonstrated with microorganisms other than specified microorganisms.\n\nTissue subjected to processing\n\n (3) Human musculoskeletal tissue that is subjected to processing prior to packaging (including, for example, a bioburden reduction process) must be:\n\n (a) sampled for bioburden testing at the time of collection or prior to the processing to exclude tissue contaminated with specified microorganisms; and\n\n (b) either:\n\n (i) sampled for bioburden testing after the processing and must demonstrate no microbial contamination; or\n\n (ii) subjected to a bioburden reduction process that has been validated to render the tissue free from any microbial contamination.\n\n (4) Human musculoskeletal tissue that demonstrates:\n\n (a) contamination with specified microorganisms when tested in accordance with paragraph 21(3)(a); or\n\n (b) any microbial contamination when tested in accordance with subparagraph 21(3)(b)(i);\n\nmust be rejected for therapeutic use.\n\n22  Demineralised products\n\n  The residual calcium of human musculoskeletal tissue products that are demineralised must not exceed 8% w/w.\n\n23  Freeze‑dried products\n\n  The residual moisture content of human musculoskeletal tissue products that are freeze‑dried must not exceed 6% w/w.\n\n24  Storage and transportation\n\n  Human musculoskeletal tissue products must be:\n\n (a) stored as follows:\n\n (i) at minus 20°C to minus 40°C for not more than 6 months after the collection of the human musculoskeletal tissue; or\n\n (ii) frozen or cryopreserved at less than minus 40°C for not more than 5 years after the collection of the human musculoskeletal tissue; or\n\n (iii) if the products are freeze‑dried—at room temperature for not more than 5 years after the collection of the human musculoskeletal tissue; or\n\n (iv) in accordance with conditions that are validated on the basis of validated data or documented evidence from relevant scientific literature, including justified time and temperature specifications, to ensure the quality, safety and efficacy of the products; and\n\n (b) transported in a manner that ensures the relevant storage conditions specified in paragraph (a) are maintained during transportation.\n\n\n\n\nPart 4—Standard for human cardiovascular tissue products\n\n25  What this Part is about\n\nThis Part specifies requirements that must be met in the manufacture of human cardiovascular tissue products that have been subjected to only minimal manipulation and are manufactured for allogeneic use only, including requirements relating to human cardiovascular tissue that is collected for use in the manufacture of those products.\n\nUnless otherwise specified, a biological to which this Part applies must meet the general requirements in Part 2 in addition to the specific requirements in this Part.\n\n26  Application of this Part\n\n  This Part applies in relation to human cardiovascular tissue products that:\n\n (a) have been subjected to only minimal manipulation; and\n\n (b) are manufactured for allogeneic use only.\n\n27  Tissue not subjected to a bioburden reduction process\n\n (1) Human cardiovascular tissue that is not subjected to a bioburden reduction process must be collected, subjected to any processing prior to packaging, sampled for bioburden testing, packaged in an operating theatre, transported to a manufacturing site, and cryopreserved.\n\n (2) The cryopreservation of human cardiovascular tissue mentioned in subsection (1) must commence:\n\n (a) in the case of a deceased donor—within 48 hours of asystole; or\n\n (b) in the case of a living donor—within 48 hours of collection.\n\n (3) Human cardiovascular tissue that is sampled in accordance with subsection (1) must be tested for bioburden and, following that testing, must:\n\n (a) demonstrate no microbial contamination; or\n\n (b) be rejected for therapeutic use if microbial contamination is demonstrated.\n\n28  Tissue subjected to a bioburden reduction process\n\n (1) Human cardiovascular tissue that is subjected to a bioburden reduction process must be processed and treated with antimicrobial agents in accordance with subsections (2) and (3).\n\n (2) The processing and treatment with antimicrobial agents must commence:\n\n (a) in the case of a deceased donor—within 36 hours of asystole; or\n\n (b) in the case of a living donor—within 36 hours of collection.\n\n (3) The human cardiovascular tissue must be exposed, between dissection of the tissue from its surrounding tissue and the time of its cryopreservation, to conditions of antimicrobial treatment at:\n\n (a) 34°C to 39°C for 6 to 12 hours; or\n\n (b) 2°C to 8°C for 18 to 24 hours.\n\n (4) Following the bioburden reduction process and before the addition of cryopreservative, human cardiovascular tissue must be sampled, and tested for bioburden and, following testing, must:\n\n (a) demonstrate no microbial contamination; or\n\n (b) be rejected for therapeutic use if microbial contamination is demonstrated.\n\n (5) Human cardiovascular tissue that is subjected to a bioburden reduction process must be cryopreserved:\n\n (a) within 72 hours of asystole; or\n\n (b) within a longer timeframe that is validated by the manufacturer to prevent microbial proliferation and to ensure the quality, safety and efficacy of the human cardiovascular product manufactured using the tissue.\n\n29  Heart valves\n\n  Human cardiovascular tissue that is a heart valve must be a competent valve prior to cryopreservation.\n\n30  Storage and transportation\n\nHuman cardiovascular tissue\n\n (1) Immediately following collection and prior to processing in accordance with either section 27 or 28, human cardiovascular tissue must be:\n\n (a) stored as follows:\n\n (i) at a temperature between 0°C to 10°C; or\n\n (ii) as otherwise validated by the manufacturer to prevent microbial proliferation and to ensure the quality, safety and efficacy of the human cardiovascular tissue product manufactured using the tissue; and\n\n (b) transported in a manner that ensures the relevant storage conditions specified in paragraph (a) are maintained during transportation.\n\nHuman cardiovascular tissue products\n\n (2) Human cardiovascular tissue products that are cryopreserved must be stored as follows:\n\n (a) at or below minus 100°C for not more than 5 years after collection of the human cardiovascular tissue; or\n\n (b) in accordance with conditions that are validated on the basis of validated data or documented evidence from relevant scientific literature, including justified time and temperature specifications, to ensure the quality, safety and efficacy of the products.\n\n (3) Human cardiovascular tissue products that are cryopreserved must be transported in a manner that ensures the relevant storage conditions specified in subsection (2) are maintained during transportation.  \n\n\nPart 5—Standard for human ocular tissue products\n\n31  What this Part is about\n\nThis Part specifies requirements that must be met in the manufacture of human ocular tissue products that have been subjected to only minimal manipulation and are manufactured for allogeneic use only, including requirements relating to human ocular tissue that is collected for use in the manufacture of those products.\n\nUnless otherwise specified, a biological to which this Part applies must meet the general requirements in Part 2 in addition to the specific requirements in this Part.\n\n32  Application of this Part\n\n  This Part applies in relation to human ocular tissue products that:\n\n (a) have been subjected to only minimal manipulation; and\n\n (b) are manufactured for allogeneic use only.\n\n33  Collection\n\n (1) Collection of human ocular tissue from a deceased donor must be completed not later than 48 hours after asystole, and the time intervals between asystole, enucleation, preservation and corneal excision must be documented.\n\n (2) A human ocular tissue product that is manufactured using human ocular tissue collected between 24 and 48 hours after asystole must not be released for supply unless:\n\n (a) a medical practitioner acting for, or on behalf of, the manufacturer or the sponsor has evaluated the quality, safety and efficacy of the product; and\n\n (b) the medical practitioner who is responsible for the administration to, or application in the treatment of, the recipient of the product has been notified that the collection occurred between 24 and 48 hours after asystole; and\n\n (c) the medical practitioners mentioned in paragraphs (a) and (b) are registered in a State or internal territory.\n\n34  Storage and transportation\n\n  Human ocular tissue products must be stored as follows:\n\n (a) in the case of an eye globe—in a moist chamber system at 0°C to 10°C for not more than 48 hours after collection of the eye globe; or\n\n (b) in the case of excised cornea—either:\n\n (i) in a corneal storage medium at 0°C to 10°C for not more than 14 days after collection of the cornea; or\n\n (ii) in a storage medium at 28°C to 37°C for not more than 30 days after collection of the cornea; or\n\n (iii) in a cryopreservation medium between minus 75°C to minus 196°C for not more than 2 years after the collection of the cornea; or\n\n (c) in the case of sclera—maintained in at least 75% v/v ethanol solution for not more than 1 year after collection of the sclera; or\n\n (d) in accordance with conditions that are validated on the basis of validated data or documented evidence from relevant scientific literature, including justified time and temperature specifications, to ensure the quality, safety and efficacy of the products.\n\n35  Excised cornea—testing of storage medium etc.\n\n (1) Where excised cornea is stored in accordance with subparagraph 34(b)(ii), then:\n\n (a) the storage medium must be tested for microbial contamination using a validated test method prior to transfer of the tissue to a transport medium; and\n\n (b) subsequent exposure to the transport medium at a temperature validated to maintain tissue quality must not exceed 5 days.\n\n (2) If testing of the storage medium in accordance with paragraph (1)(a) demonstrates evidence of microbial contamination, then:\n\n (a) where the excised cornea has not been released for supply—the excised cornea must be rejected for therapeutic use; or\n\n (b) where the excised cornea has been released for supply—the results of the microbial tests must be reported to the medical practitioner who is responsible for the administration to, or application in the treatment of, the recipient of the product in accordance with the documented procedures of the manufacturer.\n\n36  Containers\n\n  A human ocular tissue product must be sealed within a sterile container and must be packaged so as to:\n\n (a) prevent ingress or egress of all materials; and\n\n (b) ensure that any breach of integrity of the container and packaging is evident.\n\n37  Examination and evaluation\n\n  Examination and evaluation of human ocular tissue must be in accordance with the requirements set out in section 10 of the EBAANZ Standards for Eye Donation and Eye Tissue Banking.\n\n\n\n\nPart 6—Standard for human skin products\n\n38  What this Part is about\n\nThis Part specifies requirements that must be met in the manufacture of human skin products that have been subjected to only minimal manipulation, including requirements relating to human skin that is collected for use in the manufacture of those products.\n\nUnless otherwise specified, a biological to which this Part applies must meet the general requirements in Part 2 in addition to the specific requirements in this Part.\n\n39  Application of this Part\n\n  This Part applies in relation to human skin products that have been subjected to only minimal manipulation.\n\n40  Processing etc.\n\n (1) Human skin must be sampled for bioburden testing following collection and prior to being packaged.\n\n (2) Processing of human skin must commence:\n\n (a) within 24 hours of collection; or\n\n (b) within a longer timeframe that is validated by the manufacturer to prevent microbial proliferation and to ensure the quality, safety and efficacy of the human skin product manufactured using the human skin.\n\n41  Bioburden testing\n\n (1) Human skin sampled in accordance with subsection 40(1) must be tested for bioburden and, following that testing, must:\n\n (a) demonstrate no microbial contamination with specified microorganisms; or\n\n (b) be rejected for therapeutic use if microbial contamination with specified microorganisms is demonstrated.\n\n (2) If bioburden testing in accordance with subsection (1) demonstrates microbial contamination with microorganisms other than specified microorganisms, then the results of the testing must be reported by the manufacturer of the human skin product to the medical practitioner who is responsible for the administration to, or application in the treatment of, the recipient of the product.\n\n42  Freeze‑dried products\n\n  The residual moisture content of human skin products that are freeze‑dried must be less than 5%.\n\n43  Storage and transportation\n\nHuman skin\n\n (1) Immediately following collection and prior to processing, human skin must be:\n\n (a) stored as follows:\n\n (i) at less than 10°C in a suitable storage medium; or\n\n (ii) as otherwise validated by the manufacturer to prevent microbial proliferation and to ensure the quality, safety and efficacy of the human skin product manufactured using the human skin; and\n\n (b) transported in a manner that ensures the relevant storage conditions specified in paragraph (a) are maintained during transportation.\n\nHuman skin products\n\n (2) Human skin products must be stored as follows:\n\n (a) at less than minus 40°C for not more than 5 years after collection of the human skin; or\n\n (b) at 2°C to 8°C for not more than 14 days after collection of the human skin; or\n\n (c) if stored in greater than 75% glycerol solution—at 2°C to 8°C for not more than 2 years after the collection of the human skin; or\n\n (d) in accordance with conditions that are validated on the basis of validated data or documented evidence from relevant scientific literature, including justified time and temperature specifications, to ensure the quality, safety and efficacy of the products.\n\n (3) Human skin products must be transported in a manner that ensures the relevant storage conditions specified in subsection (2) are maintained during transportation.\n\n\n\n\nPart 7—Standard for human amnion products\n\n44  What this Part is about\n\nThis Part specifies requirements that must be met in the manufacture of human amnion products that have been subjected to only minimal manipulation, including requirements relating to human amnion that is collected for use in the manufacture of those products.\n\nUnless otherwise specified, a biological to which this Part applies must meet the general requirements in Part 2 in addition to the specific requirements in this Part.\n\n45  Application of this Part\n\n  This Part applies in relation to human amnion products that have been subjected to only minimal manipulation.\n\n46  Collection etc.\n\n (1) Human amnion used in the manufacture of human amnion products must be collected as soon as possible after caesarean section or vaginal delivery.\n\n (2) Processing of the human amnion must commence:\n\n (a) within 24 hours of collection; or\n\n (b) within a longer timeframe that is validated by the manufacturer to prevent microbial proliferation and to ensure the quality, safety and efficacy of the human amnion product manufactured using the human amnion.\n\n47  Terminal sterilisation\n\n  Human amnion products manufactured using human amnion collected following vaginal delivery must be terminally sterilised in accordance with section 14.\n\n48  Dehydrated or freeze‑dried products\n\n  The residual moisture content of human amnion products that are dehydrated or freeze-dried must be less than 15%.\n\n49  Storage and transportation\n\nHuman amnion\n\n (1) Immediately following collection and prior to processing, a human amnion must be:\n\n (a) stored at less than 10°C in a suitable storage medium, or as otherwise validated by the manufacturer to prevent microbial proliferation and to ensure the quality and safety of the human amnion; and\n\n (b) transported in a manner that ensures the relevant storage conditions specified in paragraph (a) are maintained during transportation.\n\nHuman amnion products\n\n (2) Human amnion products must be stored as follows:\n\n (a) if the products are cryopreserved—at less than minus 80°C for not more than 2 years after collection of the human amnion; or\n\n (b) if the products are dehydrated or freeze-dried—at room temperature for not more than 5 years after collection of the human amnion; or\n\n (c) in accordance with conditions that are validated on the basis of validated data or documented evidence from relevant scientific literature, including justified time and temperature specifications, to ensure the quality, safety and efficacy of the products.\n\n (3) Human amnion products must be transported in a manner that ensures the relevant storage conditions specified in subsection (2) are maintained during transportation.\n\n \n","sortOrder":0}],"analysis":{"flash_summary":{"complexity_score":7,"scope_assessment":{"changed":false,"description":"This instrument consolidates and modernises pre‑existing tissue and human biological standards (replacing earlier Therapeutic Goods Orders) and adds a single general standard that applies across tissue types while retaining specific standards per tissue. It does not materially expand the regulatory scope (it still governs human cell and tissue derived biologicals and preserves exclusions, see s 6), but it does increase prescriptiveness and detail — adding more explicit validation, documentation, sampling and storage requirements (see ss 10–14, 16 and Parts 3–7). The change is therefore a technical consolidation and tightening of requirements rather than a substantive broadening of the kinds of products regulated."},"complexity_factors":["Seven Parts with interlocking general (Part 2) and specific standards (Parts 3–7), requiring simultaneous compliance with multiple Parts for many products (see s 5 and notes).","Approximately 49 numbered sections plus numerous subsections and notes (Parts 1–7), producing many rule permutations.","Extensive defined terms and references in the Definitions section (s 4) — roughly 25+ specific definitions including cross‑terms (e.g. HCT materials, minimal manipulation, specified microorganism).","Frequent conditional application and carve‑outs (e.g. many sections exempt certain Part 3–7 products from Part 2 clauses — see ss 12–17 and notes), producing nested exceptions.","Multiple external cross‑references to other instruments and guidance (Therapeutic Goods Act and Regulations, EBAANZ Standards, TGA Approach to TSE, EMA virus validation guidance), which require reading external documents to fully apply requirements (s 4, s 10, s 37).","Numerous technical validation requirements (validated sampling, validated test methods, validation of storage/transport conditions) that are open to interpretation and documentation (ss 10, 12, 16 and throughout Parts 3–7).","Multiple, specific time/temperature matrixes for different tissues and product forms (e.g. cryopreservation temperature ranges, maximum storage durations across Parts 3–7) increasing operational complexity.","Transitional arrangements preserving prior Therapeutic Goods Orders during a 12‑month transition window (s 7), creating short‑term dual‑compliance risk for organisations."],"plain_english_summary":"**What this instrument does (mechanically)\n\n- Establishes a set of mandatory technical standards for the manufacture, testing, storage, packaging and transport of \"biologicals\" derived from human cells and tissues. (The instrument is made under the Therapeutic Goods Act — see Definitions and Authority.)\n- Contains a general standard that applies to all human cell and tissue–derived biologicals (Part 2), and five specific standards that apply to particular tissue types that have been subjected to only \"minimal manipulation\": musculoskeletal (Part 3), cardiovascular (Part 4), ocular (Part 5), skin (Part 6) and amnion (Part 7). (See section 5.)\n- Prescribes donor selection rules, microbial/bioburden controls and sampling, validation requirements for sterilisation and processing, timelines for collection from deceased donors, and precise storage and transport temperature/time limits for each tissue/product type. (Key requirements: ss 9–17 and Parts 3–7.)\n\nWho is affected\n\n- Manufacturers and sponsors of human cell and tissue–derived biologicals (including tissue banks and processing facilities). These entities must implement the specified testing, validation, documentation and storage systems. (See ss 5, 10–13, 16.)\n- Clinical staff and registered medical practitioners: they may be required to evaluate products manufactured outside preferred criteria (for example where donor disease criteria cannot be met) and to be notified in some cases (e.g. ocular tissue collected 24–48 hours after asystole). (See ss 9, 33.)\n- Transport and cold‑chain providers and packaging suppliers, because the instrument prescribes secure packaging and specific validated time/temperature conditions. (See ss 16, 17 and the storage sections in Parts 3–7.)\n- The regulator (TGA) and auditors/enforcement bodies, who will assess compliance under the Therapeutic Goods Act.\n\nWhy it matters (stated purpose, then practical effects)\n\n- Official purpose-claim: to minimise infectious risk and ensure the quality, safety and efficacy of therapeutic biologicals derived from human cells and tissues by setting technical, validated minimum standards. (See the general framing in Part 2 and the specific requirements in Parts 3–7.)\n\n- Practical effects and trade-offs:\n  - Safety and traceability: the instrument raises the baseline of required sampling, validated testing methods, documentation and storage/transport controls (ss 11–13, 16). That centralises safety responsibilities on manufacturers and sponsors.\n  - Compliance costs: manufacturers must invest in validated test methods, sampling protocols, sterility/virus‑validation studies, validated storage/cryopreservation equipment and documented quality systems (s 10, s 12, s 14). These are recurring operational costs and capital expenditures for smaller suppliers.\n  - Operational constraints and timing pressure: the instrument prescribes tight collection and processing windows for deceased donors and specific temperature/time windows for storage and transport that change normal logistics and staffing patterns (ss 15, 20, 27–28, 33, 40, 46, and storage clauses in Parts 3–7).\n  - Clinical discretion limited but present: where donor or collection criteria cannot be met, an authorised medical practitioner may approve and document the use (s 9). This creates a documented exception process rather than unlimited discretion.\n  - Market effects: additional technical requirements may favour larger or better‑capitalised manufacturers who can absorb validation and cold‑chain costs; smaller operators face higher barriers to compliance (implicit from the validation and documentation obligations in ss 10–13, 16).\n\nKey technical requirements to note (examples and where found)\n\n- Donor disease/eligibility: Do not use HCT materials from donors known to have diseases that compromise the product unless justified by validated criteria or medical practitioner sign‑off (s 9).\n- Critical materials: suppliers must ensure materials do not introduce contamination, and many solutions must be sterile or meet specified sterility requirements; human/animal sourced critical materials must meet TGA TSE approach and virus‑validation guidance (s 10).\n- Microbial/bioburden controls: implement a risk‑based contamination control strategy, use validated sampling and test methods, and define specified microorganisms on a risk basis (ss 11–13).\n- Sterilisation validation: terminal sterilisation must meet a sterility assurance level of 10^-6 (s 14).\n- Collection timing: strict time windows after asystole for collection and processing of deceased‑donor tissue (ss 15, 20, 27–28, 33).\n- Storage and transport: specific temperatures and maximum storage durations are set for each tissue/product type (see ss 16, 24, 30, 34, 43, 49). Example: cryopreserved cardiovascular products—at or below −100°C for up to 5 years (s 30(2)(a)).\n- Containers and packaging: sterile containers, minimum double‑packaging and integrity indicators are mandated (s 17; ocular tissue has separate packaging rules in s 36).\n\nWho pays, who decides, and what behaviour changes\n\n- Who pays: the manufacturer/sponsor bears the cost of testing, validation, storage, packaging and recordkeeping required by the instrument (ss 10–14, 16–17). Health providers may incur downstream costs (e.g. of notifying clinicians where contamination is detected — Part 5, s 35(2)).\n- Who decides: manufacturers/sponsors decide operational implementation (validation, sampling methodology, QC limits) within the framework of the instrument; registered medical practitioners can authorise documented exceptions in some circumstances (s 9). The TGA enforces compliance under the Therapeutic Goods Act and may rely on registers and published guidance (s 10 references to the Register and external guidance documents).\n- Behavioural change required: entities must adopt validated sampling and test methods, stricter donor screening or documented medical approvals for exceptions, defined cold‑chain and packaging practices, and stronger recordkeeping and reporting procedures.\n\nCompliance, implementation and risk observations\n\n- Compliance burden: multiple validation requirements (sampling, test methods, sterility, cryopreservation) and detailed storage/transport specs increase administrative and technical burden on manufacturers (ss 10–14, 16, Parts 3–7).\n- Implementation risk: manufacturers must generate or rely on validated data or literature to justify deviations (s 9, s 16(1)(a)(ii), various storage clauses), which can be resource‑intensive and produce disputes over acceptable validation evidence.\n- Enforcement and discretion: the instrument sets technical minima, but leaves many choices to manufacturers about validation approaches and to medical practitioners about approving exceptions—this channels regulatory discretion into documentary review and retrospective audit rather than case‑by‑case rulemaking (see s 9 and multiple \"validated by the manufacturer\" clauses).\n\nExceptions and scope limits\n\n- The instrument does not apply to faecal microbiota transplant products, certain items listed in the Regulations (Schedule 5A item 13, subject to conditions), or biopsy samples collected only for in‑vitro diagnostics that will not be used for further manufacture or transplantation (s 6).\n- Parts 3–7 apply only to products subjected to \"only minimal manipulation\" and, in many cases, only to products intended for allogeneic use; other products remain subject to Part 2 or other regulatory requirements (s 5 and the application clauses in Parts 3–7).\n\nPrimary sections to consult quickly\n\n- General rules: ss 8–17 (Part 2)\n- Musculoskeletal: ss 18–24 (Part 3)\n- Cardiovascular: ss 25–30 (Part 4)\n- Ocular: ss 31–37 (Part 5)\n- Skin: ss 38–43 (Part 6)\n- Amnion: ss 44–49 (Part 7)\n\nSummary sentence\n\nTGO 109 consolidates and prescribes a harmonised set of technical requirements for human cell and tissue–derived biologicals—covering donor selection, contamination control, validated testing and sterility, collection timing, storage/transport temperatures and packaging—shifting the primary burden for safety validation and recordkeeping onto manufacturers and sponsors while retaining narrow medical practitioner sign‑offs for certain exceptions (see ss 5, 9–17, Parts 3–7)."},"flash_summary_failed":{"failed":true,"reason":"A positive credit balance is required for all requests, including BYOK, so fallback providers remain available. Add credits at https://vercel.com/d?to=%2F%5Bteam%5D%2F%7E%2Fai%3Fmodal%3Dtop-up to continue.","source":"analysis-cron"},"kimi_summary":{"content_quality":"ok","complexity_score":6,"scope_assessment":{"changed":true,"description":"This instrument consolidates and replaces five previous separate Therapeutic Goods Orders (Nos. 83-86 and parts of 88) into a single instrument with a unified structure. While the core safety requirements remain similar, the scope has expanded in regulatory reach by: (1) creating a comprehensive general standard applicable to all biologicals (not just the specific tissue types previously covered), (2) adding specific standards for human amnion products which were not previously subject to a dedicated TGO, and (3) establishing clearer hierarchical relationships between general and specific requirements. The instrument also narrows scope in some areas by explicitly excluding faecal microbiota transplant products."},"complexity_factors":["Layered application structure: General standard in Part 2 applies to all biologicals, but specific Parts 3-7 modify or override specific sections for particular tissue types, requiring cross-referencing to determine which rules apply","Multiple defined terms (18+ definitions in section 4), including technical concepts like 'asystole' (cardiac death reference time), 'minimal manipulation', and 'bioburden'","Extensive cross-referencing between Parts: Sections 12-17 contain multiple subsections that 'do not apply' to specific tissue types, with notes redirecting to alternative requirements in Parts 3-7","Conditional logic with multiple variables: Requirements vary based on donor status (living vs deceased), processing method (minimal manipulation vs processed), temperature ranges, timeframes, and product type","Incorporation of external documents by reference: EBAANZ Standards for Eye Donation, TGA Approach to TSE, and European Medicines Agency virus validation guidance","Nested exceptions: Section 6 excludes faecal microbiota transplants and diagnostic biopsies; sections throughout contain exceptions to exceptions (e.g., section 13(5) excludes certain products from subsection (3), which itself contains conditional requirements)","Transitional arrangements in section 7 creating parallel compliance pathways during the 12-month transition period"],"plain_english_summary":"This law is the manufacturing rulebook for biological medicines made from human cells and tissues (e.g., bone, heart valves, corneas, skin, amnion), setting safety, sterility, testing, storage and donor‑screening expectations to prevent infections and ensure transplant quality.  \n\nIt affects tissue banks, manufacturers, hospitals and surgeons (and thereby patients), replaces five older standards with a consolidated regime, and allows a one‑year transition for industry."}},"importantCases":[],"_links":{"self":"/api/acts/therapeutic-goods-standards-for-biologicals-general-and-specific-requirements-tgo-109-order-2021","history":"/api/acts/therapeutic-goods-standards-for-biologicals-general-and-specific-requirements-tgo-109-order-2021/history","analysis":"/api/acts/therapeutic-goods-standards-for-biologicals-general-and-specific-requirements-tgo-109-order-2021/analysis","conflicts":"/api/acts/therapeutic-goods-standards-for-biologicals-general-and-specific-requirements-tgo-109-order-2021/conflicts","importantCases":"/api/acts/therapeutic-goods-standards-for-biologicals-general-and-specific-requirements-tgo-109-order-2021/important-cases","documents":"/api/acts/therapeutic-goods-standards-for-biologicals-general-and-specific-requirements-tgo-109-order-2021/documents"}}